Back to top

Image: Bigstock

Has Sangamo Therapeutics (SGMO) Outpaced Other Medical Stocks This Year?

Read MoreHide Full Article

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Sangamo Therapeutics (SGMO - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

Sangamo Therapeutics is a member of our Medical group, which includes 765 different companies and currently sits at #11 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. SGMO is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for SGMO's full-year earnings has moved 78.90% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Our latest available data shows that SGMO has returned about 2.13% since the start of the calendar year. At the same time, Medical stocks have lost an average of 1.05%. As we can see, Sangamo Therapeutics is performing better than its sector in the calendar year.

To break things down more, SGMO belongs to the Medical - Biomedical and Genetics industry, a group that includes 283 individual companies and currently sits at #111 in the Zacks Industry Rank. This group has lost an average of 4.74% so far this year, so SGMO is performing better in this area.

Investors in the Medical sector will want to keep a close eye on SGMO as it attempts to continue its solid performance.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Sangamo Therapeutics, Inc. (SGMO) - free report >>